CRISPR Therapeutics to present Phase 1b CTX310 data in severe hypertriglyceridemia at AHA 2026
CRSP•CRISPR Therapeutics flagged late-breaking Phase 1b clinical data for CTX310 in severe hypertriglyceridemia for AHA Scientific Sessions 2026. The oral presentation is scheduled for Nov. 9, 2026, at 8:00 a.m. CST; results have not been disclosed.
1. Presentation scheduled
CRISPR Therapeutics said late-breaking Phase 1b clinical data for CTX310 in severe hypertriglyceridemia are scheduled for an oral presentation at AHA Scientific Sessions 2026 on Nov. 9, 2026, at 8:00 a.m. CST. The company did not disclose outcomes, citing an embargo until the presentation.
2. CTX310 program
CTX310 is an in vivo CRISPR/Cas9 liver-editing program targeting ANGPTL3 and is part of a broader cardiometabolic pipeline.
